December 6, 2023

ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A.

December 1, 2023

Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results.

November 29, 2023

ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.

November 21, 2023

ARUP experts seek to increase understanding of the FDA’s proposed rule to regulate lab-developed tests as medical devices and the impact on hospitals and patients during a webinar on November 29.

November 10, 2023

ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.

November 9, 2023

ARUP experts in molecular pathology will present at, participate in, and be available to attendees during the upcoming Association for Molecular Pathology (AMP) Meeting and Expo in Salt Lake City.

November 6, 2023

ARUP’s David P. Ng, MD, will share a presentation on artificial intelligence (AI) in the clinical lab at the Patient-centered Laboratory Utilization Guidance Services (PLUGS) Regional Summit.

October 26, 2023

The newest edition highlights innovations that keep ARUP at the forefront of toxicology testing. Also featured: ARUP’s expanded capacity for cytogenetics testing.